ORCID Profile
0000-0002-4681-9893
Current Organisation
University of Calgary
Does something not look right? The information on this page has been harvested from data sources that may not be up to date. We continue to work with information providers to improve coverage and quality. To report an issue, use the Feedback Form.
Publisher: Informa UK Limited
Date: 29-12-2020
Publisher: JMIR Publications Inc.
Date: 08-03-2016
DOI: 10.2196/RESPROT.5261
Publisher: Wiley
Date: 07-07-2022
DOI: 10.1002/ACR.24621
Abstract: The aim of this study was to quantify costs of hospital‐associated care for juvenile idiopathic arthritis (JIA), provide insights in patient‐level variation in costs, and investigate costs over time from the moment of JIA diagnosis. Results were reported for all JIA patients in general and by subtype. This study was a single‐center, retrospective analysis of prospective data from electronic medical records of children with JIA, ages 0–18 years, between April 1, 2011 and March 31, 2019. Patient characteristics (age, sex, JIA subtype) and hospital‐based resource use (consultations, medication, radiology procedures, laboratory testing, surgeries, emergency department [ED] visits, hospital stays) were extracted and analyzed. Unit prices were obtained from Dutch reimbursement lists and pharmaceutical and hospital list prices. The analysis included 691 patients. The mean total cost of hospital care was €3,784 atient/year, of which €2,103 (55.6%) was attributable to medication. Other costs involved pediatric rheumatologist visits (€633 atient/year [16.7%]), hospital stays (€439 atient/year [11.6%]), other within‐hospital specialist visits (€324 atient/year [8.6%]), radiology procedures (€119 atient/year [3.1%]), laboratory tests (€114 atient/year [3.0%]), surgeries (€46 atient/year [1.2%]), and ED visits (€6 atient/year [0.2%]). Mean annual total costs varied between JIA subtypes and between in iduals and were the highest for systemic JIA (€7,772 atient/year). Over the treatment course, costs were the highest in the first month after JIA diagnosis. Hospital care costs of JIA vary substantially between in iduals, between subtypes, and over the treatment course. The highest annual costs were for systemic JIA, primarily attributable to medication (i.e., biologics). Costs of other hospital‐associated care were comparable regardless of subtype.
Publisher: Springer Science and Business Media LLC
Date: 24-03-2022
DOI: 10.1007/S40271-022-00575-X
Abstract: Few studies have examined pediatric rheumatologists' approaches to treatment decision making for biologic therapy for patients with juvenile idiopathic arthritis (JIA). This study presents the qualitative research undertaken to support the development of a Best-Worst Scaling (BWS) survey for tapering in JIA. The study objectives were to (1) describe the treatment decision-making process of pediatric rheumatologists to initiate and taper biologics and (2) select attributes for a BWS survey. Pediatric rheumatologists across Canada were recruited to participate in interviews using purposeful s ling. Interviews were conducted until saturation was achieved. Interview recordings were transcribed verbatim and transcripts were analyzed using deductive thematic analysis. Initial codes were organized into themes and subthemes using an iterative process. Attributes for the BWS survey were developed from these themes and a literature review was conducted in parallel to inform survey development. Further refinement of the attributes was done through consultation with the research team. Five pediatric rheumatologists participated in the interviews. Shared decision making was part of the approach to initiating and tapering biologics in their practice. Tapering approaches differed some pediatric rheumatologists preferred to stop biologics immediately, while others tapered by reducing dose and/or increasing the dose interval over time. A total of 14 attributes were developed for the BWS. Thirteen attributes were selected from the themes that emerged from the qualitative interviews and one attribute was included after review with the research team. Attributes related to patient characteristics included JIA subtype, time in remission, history or presence of joint damage or erosive disease, how challenging it was to achieve remission, and history of flares. Contextual attributes included accessibility of biologics and willingness to taper biologics. This study contributes to the limited literature on pediatric rheumatologists' approaches to treatment decision making for biologics in JIA and identifies attributes that affect the decision to both initiate and taper. Further research is planned to implement the BWS survey to understand the importance of the attributes identified. Additional investigation is required to determine if these characteristics align with patient and parent preferences.
Publisher: Springer Science and Business Media LLC
Date: 19-05-2023
Publisher: American Chemical Society (ACS)
Date: 15-02-2017
DOI: 10.1021/ACS.INORGCHEM.6B02905
Abstract: Polycrystalline s les, prepared by a solid-state route, of compositions in the solid solution CeMn
No related grants have been discovered for Gillian Currie.